Pharmaceutical companies are increasingly working in partnership with other firms, academia, and catapults through collaborative models, in the search to discover and develop new medicines, says a new report out today.
The research and development (R&D) Sourcebook from the Association of the British Pharmaceutical Industry (ABPI) Open for Innovation: UK Biopharma R&D Sourcebook 2016 reveals how this step change towards collaborative working and open innovation – a contrast to the older model of closed corporate research and development labs – continues to support the UK economy. The report reveals that the pharmaceutical industry in the UK continues to be the highest spending sector on R&D, investing £4.2bn in 2015 – equating to a fifth of all UK business research and development spending.
The latest figures demonstrate how pharmaceutical organisations have increased their absolute level of investment in collaborative and outsourced drug discovery in the UK over the last five years, with collaborations showing particular strength in oncology and rheumatology. As well as a change to investment models, the sourcebook shows an ongoing change in focus of research into new medicines. Projects and investments increasingly address unmet need, such as rare diseases and cancer, and the UK shows great strength in both of these areas.
The sourcebook builds on last year's Adapting the Innovation Landscape: UK Biopharma R&D Sourcebook 2015 and offers the most up to date information on UK R&D, the way that medicines are developed and the context in which this takes place within the UK economy through data and analysis from Clarivate Analytics.
Dr Virginia Acha, Executive Director – Research, Medical and Innovation at the ABPI, said:
"We are in a period of great change, not least with the UK embarking on a journey outside of the EU, but also as an industry. It is therefore vital for the future discovery and development of medicines that we continue to collaborate and explore outside of our companies, industry and sector. By focusing on open innovation, this sourcebook aims to shed light on the complex, changing face of the pharmaceutical industry."
Dr Neil Weir, Senior Vice President of Discovery UCB and Chair of the ABPI Innovation Board, contributed to the sourcebook and commented in his introduction:
"The Government has announced the intention to use the forthcoming industrial strategy to mark our path forward for the UK, particularly given the decision to leave the European Union. We believe that life sciences should be central to that industrial strategy, and that critical to that strategy will be exploration about how the UK can be a global leader in the practices that will help us to be open for innovation."
The sourcebook considers four key areas:
Global health and the role of biopharma
Investing in innovation
Driving clinical research to deliver medicines
Collaborating for innovation
In addition to the core data, the guest essays provide further detail on how new collaborative models are working. James Wilsdon, Professor of Research Policy at the University of Sheffield, explores the policies and incentives that drive academic-industry collaboration and David Roblin, Chief Operating Officer and Director of Scientific Translation at the Francis Crick Institute, discusses their unique approach to open innovation.
## ENDS ##
All of the findings listed in the release are pulled directly from the R&D Sourcebook: 1 3.2 2 3.5 3 4.6 4 5.1 5 5.6 6 5.7 7 5.8 8 5.10 9 5.11 10 6.1 11 6.10
ABPI Press OfficeEmail: email@example.comTelephone during work hours (9am to 5pm Monday to Friday): +44 (0) 20 7747 7147 or +44 (0) 20 7747 1441Telephone out of hours (5pm to 9am and weekends): +44 (0) 20 7747 1445
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.